Tris Digital Health Forms, Will Focus on Digital Diagnostic Platform for ADHD
Tris Pharma Inc has announced a licensing agreement with Braingaze Ltd and the establishment of Tris Digital Health. Tris Digital Health will concentrate on developing and distributing digital diagnostic and therapeutic products for the treatment of attention-deficit/hyperactivity disorder (ADHD) and other neurological health disorders.1
Other Articles in this Edition
ADHD often goes undetected in adults, experts say
Staying Fit Boosts Kids’ Mental Health
Decision-making deficits predict social difficulties in children with ADHD
Inhibition in ADHD: Girls Are Slow to Respond, Boys Have Poor Cognitive Control
Psychedelic microdosing: A new frontier for treating ADHD symptoms and emotional dysregulation
A deep dive into Qbtech’s diagnostic ADHD test
Off-Label Use of ADHD Medications for Patients With Bipolar Disorder
Connections Between Food Additives and Psychiatric Disorders
Tris Digital Health Forms, Will Focus on Digital Diagnostic Platform for ADHD
How to improve focus: Try these 5 tips to increase attention span